A Phase 3 interventional study of Botulinum toxin type A and normal Saline in Benign Masseteric Hypertrophy, sponsored by Huons Biopharma. Active, not recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.
Sponsored by Huons Biopharma (part of Huons Global) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A double-blind, randomized, placebo-controlled, multi-center, phase III study to evaluate the efficacy and safety of LIZTOX in subjects with benign Masseteric hypertrophy
Huons Biopharma is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Botulinum toxin type A
Drug: normal Saline
Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Average change from baseline in masseter muscle thickness on both sides at maximum clenching
The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.
Time frame: 12weeks
Average change from baseline in masseter muscle thickness on both sides at maximum clenching
The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.
Time frame: 4, 8, 16, 20, 24weeks
Average change from baseline in masseter muscle thickness on both sides at rest
The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.
Time frame: 4, 8, 12, 16, 20, 24weeks
Average rate change from baseline in masseter muscle thickness on both sides at maximum clenching
The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.
Time frame: 4, 8, 12, 16, 20, 24weeks
Average rate change from baseline in masseter muscle thickness on both sides at rest
The thickness of the masseter muscle is measured using ultrasonography, and the average value is obtained from three measurements.
Time frame: 4, 8, 12, 16, 20, 24weeks
Change from baseline in the lower facial volume at maximum clenching and at rest using Morpheus 3D imaging
When measuring, the volume of the lower face was measured twice and the average value was used.
Time frame: 4, 8, 12, 16, 20, 24weeks
Rate of change from baseline in the lower facial volume at maximum clenching and at rest using Morpheus 3D imaging
When measuring, the volume of the lower face was measured twice and the average value was used.
Time frame: 4, 8, 12, 16, 20, 24weeks
The proportion of subjects who reported an overall improvement of more than 50% at maximum clenching and at rest.
Overall improvement criteria: +4 (100% complete improvement) \~ -4 (100% very marked worsening)
Time frame: 4, 8, 12, 16, 20, 24weeks
The proportion of subjects who rated overall satisfaction as 'satisfied' at maximum clenching and at rest
Overall satisfaction criteria: grade 1 (very dissatisfied) \~ grade 7 (very satisfied), Grade 6 or higher (satisfied, very satisfied) is evaluated as satisfied.
Time frame: 4, 8, 12, 16, 20, 24weeks
The proportion of subjects with a masseter muscle hypertrophy scale (MMHS) ≤3
MMHS Evaluation criteria: The facial contour and the condition of the bilateral masseter muscles are assessed on a scale from grade 1 (minimal) to grade 5 (very marked).
Time frame: 4, 8, 12, 16, 20, 24weeks
Ran from Jul 2023 to primary completion in Mar 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A